Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Apollo Endosurgery Inc | 48 |
| 2 | Opna Bio SA | 20 |
| 3 | Allergan Inc | 19 |
| 4 | Amorepacific Corp | 6 |
| 5 | Otsuka America Pharmaceutical Inc | 5 |
| 6 | Symrise AG | 4 |
| 7 | University of California San Diego UCSD | 4 |
| 8 | Corning Inc | 3 |
| 9 | Lpath Therapeutics Inc | 3 |
| 10 | Yissum Research Development Co of Hebrew University of Jerusalem | 3 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 139 |
| 2 | A61P | Therapeutic activity (drug indications) | 124 |
| 3 | C07K | Peptides | 60 |
| 4 | G01N | Investigating / analysing materials | 47 |
| 5 | C07D | Heterocyclic compounds | 44 |
| 6 | C12N | Microorganisms, enzymes | 27 |
| 7 | C07F | Organometallic compounds | 23 |
| 8 | C12Q | Measuring/testing involving enzymes | 15 |
| 9 | A61Q | Cosmetics, personal care | 14 |
| 10 | C07C | Acyclic and carbocyclic compounds | 13 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Application of sphingosylphosphorylcholine (SPC) in preparation of medicine for promoting endogenesis heart stem cells to be differentiated into heart lineage cells | 2015 | SHANDONG UNIVERSITY | 5 |
| Application of sphingosylphosphorylcholine in preparing anti-breast cancer drugs | 2016 | SHANDONG UNIVERSITY | 1 |
| Use of sphingosylphosphorylcholine antagonist for restoring the expression of antimicrobial peptides | 2009 | Amorepacific Corp | 1 |
| Sphingosylphosphocholine is preparing the application that rush endogenous heart stem cell is divided into cardiac linage cell drug | 2017 | SHANDONG UNIVERSITY | 0 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Lysosomal Storage Disorders Research | 2 |
| 2 | Lipid Membrane Structure and Behavior | 1 |
| 3 | Protein Kinase Regulation and GTPase Signaling | 1 |
| 4 | Sphingolipid Metabolism and Signaling | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Jing Zhao | Shandong University | 11 |
| 2 | Dagmar Meyer zu Heringdorf | Essen University Hospital | 10 |
| 3 | Hiroko Kishi | Yamaguchi University | 8 |
| 4 | Jae Ho Kim | Pusan National University | 8 |
| 5 | Eun Su Jeon | Pusan National University | 7 |
| 6 | Kid Törnquist | Minerva Foundation | 7 |
| 7 | Fumikazu Okajima | Gunma University | 6 |
| 8 | Genji Imokawa | Kao Corporation (Japan) | 6 |
| 9 | Ki‐Beom Suhr | Chungnam National University | 6 |
| 10 | Chang Hoon Lee | Dongguk University | 5 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Sphingosylphosphorylcholine is a ligand for ovarian cancer G-protein-coupled receptor 1 | 2000 | 290 | Protein Kinase Regulation and GTPase Signaling |
| Diagnostic tests for Niemann-Pick disease type C (NP-C): A critical review | 2016 | 144 | Lysosomal Storage Disorders Research |
| A novel membrane receptor with high affinity for lysosphingomyelin and sphingosine 1‐phosphate in atrial myocytes. | 1996 | 127 | Cellular transport and secretion |
| Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months | 2018 | 121 | Lysosomal Storage Disorders Research |
| Quantitative Measurement of Sphingosine 1-Phosphate by Radioreceptor-Binding Assay | 2000 | 108 | Lipid Membrane Structure and Behavior |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and chemical structure of Lysosphingomyelin?
Which organizations hold the most patents related to Lysosphingomyelin?
What are the main research topics associated with Lysosphingomyelin?
Who are the most prolific authors publishing on Lysosphingomyelin?
What are the key patent classifications for Lysosphingomyelin-related inventions?